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A B S T R A C T
Objective: To characterize and compare the beta-cell function and insulin resistance among Peruvian ado-
lescents with type 2 diabetes (T2D) and their non-diabetic, overweight and lean peers.
Methods: Cross-sectional study of 54 adolescents aged 10–19 years, distributed in three sex- and age-
matched groups (n = 18): (i) adolescents with T2D; (ii) overweight adolescents without T2D; and (iii)
lean adolescents without T2D, at the Diabetes, Obesity and Nutrition Research Center in Lima, Peru. Fasting
glucose, insulin, C-peptide, and glycated hemoglobin were measured for all participants. In addition, a
two-hour oral glucose tolerance test (OGTT, 1.75 mg of glucose/kg body weight) was performed, during
which glucose and C-peptide were quantiﬁed. The homeostasis model assessment of insulin resistance
(HOMA-IR) and beta-cell function (HOMA-B) were derived for all participants, and beta-cell function was
further examined by the area under the curve (AUC) of C-peptide.
Results: The median HOMA-IR score was higher in adolescents with T2D compared to lean adolescents
(6.1 vs. 2.1; p = 0.002), but was not different from that of overweight adolescents (6.1 vs. 4.0; p = 0.322).
The median HOMA-B was higher in overweight adolescents than in lean adolescents (256.9 vs. 134.2;
p = 0.015), and adolescents with T2D (256.9 vs. 119.8; p = 0.011). The mean AUC of glucose in adoles-
cents with T2D was 1.8-fold higher than that of overweight adolescents, and 1.9-fold higher than that
of lean adolescents (p < 0.001). Although the median AUC of C-peptide in adolescents with T2D was lower
than that of overweight and lean adolescents, this difference was not statistically signiﬁcant (230.7 vs.
336.6 vs. 267.3 nmol/l120 min, respectively; p = 0.215).
Conclusion: Among Peruvian adolescents with T2D, insulin resistance is the most prominent character-
istic, rather than beta-cell dysfunction.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Type 2 diabetes (T2D) in youth is a serious public health problem
that has exhibited an epidemic growth in recent decades [1,2]. Pe-
diatric T2D is associated with both acute and chronic complications
[3], which occur more prematurely than in pediatric type 1 diabe-
tes [4,5]. Although initially noted in aﬄuent settings [6], the rise
in pediatric T2D has spread to low- and middle-income countries
(LMICs) around the world [7]. The increased vulnerability of several
of the ethnic groups living in LMICs, combined with the current ep-
idemic of childhood obesity, will likely make the contribution of
LMICs to the global T2D caseload signiﬁcant. Indeed, about 80% of
the 370 million of patients with diabetes will live in LMICs by 2030
[8].
Despite the importance of pediatric T2D in LMICs, the patho-
genesis of T2D in non-Caucasian adolescents is still unclear [9],
preventing the development of effective therapeutic strategies
for these groups. In general, T2D is thought to arise from beta-cell
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dysfunction and increased insulin resistance [10–13], usually re-
sulting fromobesity [14].However, the relative contributionof insulin
resistance and beta-cell dysfunction to the pathogenesis of T2D in
adolescents is uncertain [9], partly due to the complex metabolic
changes occurring in puberty [15,16]. Furthermore, ethnic varia-
tions in glucosemetabolism exist [17,18], and add to the uncertainty
about the pathophysiology of T2D in non-Caucasian adolescents.
Delineating the speciﬁcmetabolic defects underlying T2D in non-
Caucasian adolescents is critical for the development of effective
therapeutic strategies targeting the speciﬁc metabolic defects in
each ethnic group. This is apparent in adults, with African-Americans
exhibiting a greater response to insulin sensitizers (e.g.
thiazolidinediones), given their diminished insulin sensitivity [19].
Hispanic adolescents have a high prevalence of obesity [20,21],
type 2 diabetes [22,23], and its complications [24]. This increased
vulnerability has been linked to both environmental and genetic
factors, expressed as a lowdisposition index [25], and higher insulin
resistance than their Caucasian peers [26]. Despite these observa-
tions, evidence on ethnic variations in glucose metabolism in
Hispanics is very limited [26], particularly for Latin American ado-
lescents. Latin Americans share a common genetic ancestry, which
may affect their risk of T2D and the pathogenesis of the disease. Nev-
ertheless, the extent to which this genetic background affects the
role of insulin resistance and impairedbeta-cell function in thepatho-
genesis of T2D in Latin American adolescents is currently unknown.
In this context, we aimed to assess the beta-cell function and
insulin resistance in three groups of adolescents aged 10–19 years
in Peru: adolescents with T2D, overweight adolescents without T2D,
and lean adolescents without T2D. This evidence will improve our
understanding of the pathogenesis of diabetes in Latin American
adolescents and, more importantly, it will contribute to tailor ef-
fective and safe therapeutic strategies targeting the main metabolic
defects underlying diabetes in this population.
Materials and methods
Study design and setting
We conducted a cross-sectional study to assess the metabolic
defects in Peruvian adolescents with type 2 diabetes mellitus, by
comparing the metabolic parameters of sex- and age-matched pa-
tients with T2D, overweight and lean adolescents aged 10–19 years
at the Diabetes, Obesity and Nutrition Research Center (CIDON), in
Lima, Peru.
Participants
This study included three groups of adolescents between 10 and
19 years, matched by sex and age (within one year), in a 1:1:1
scheme: (i) adolescents with T2D, (ii) overweight or obese adoles-
cents without T2D, and (iii) lean adolescents without T2D.
Adolescents with T2D were selected randomly from a list of pa-
tients aged 10–19 years, and with T2D attending CIDON. The
diagnosis of T2D was based on the diagnostic criteria of the
International Society for Pediatric and Adolescent Diabetes,
and included: symptoms of diabetes plus casual plasma glucose
≥200mg/dl, fasting plasma glucose ≥126mg/dl or two-hour plasma
glucose ≥200mg/dl during an oral glucose tolerance test (OGTT) [27].
For the comparison groups, lean and overweight adolescents ful-
ﬁlling the eligibility and matching criteria were systematically
selected from adolescents consecutively attending CIDON. Over-
weight was deﬁned as a Body Mass Index (BMI) for age and sex at
or above the 85th percentile of the 2000 clinical growth charts of
the Center for Disease Control and Prevention [28]. Normal weight
was deﬁned as a BMI for age and sex within the 5th and 84th per-
centiles of the same standard. Adolescents with a diagnosis of with
type 1 diabetes and the presence of markers of beta-cell autoim-
munity (antibodies against glutamic acid decarboxylase, islet antigen
2, and insulin; and islet cell autoantibodies) were excluded from
the study. Participants with active concurrent illnesses were ex-
cluded from the study.
Data collection and variables
Metabolic testing took place between January 8th and March 15,
2014 at CIDON. As instructed, participants arrived at CIDON at 08:00
h on their scheduled date, after a 12-hour overnight fast. Insulin
treatment was discontinued 48 hours prior to metabolic testing, but
oral antidiabetic therapy was not modiﬁed, because close follow-
up was not possible.
A short survey was conducted to collect basic demographic data
(age, sex) and relevant clinical antecedents (family history of dia-
betes, age at diagnosis and duration of diabetes). Weight and height
were measured by experienced health professionals, using a
previously-calibrated scale and stadiometer, respectively. Vital signs
were checked prior to initiating metabolic testing. A peripheral cath-
eter was placed in the forearm and 4ml of fasting venous blood was
collected for measuring glucose, insulin, HbA1C and C-peptide.
Fifteen minutes later, a two-hour oral glucose tolerance test
(OGTT) using 1.75 g of glucose per kilogram of body weight (up to
amaximum of 75 g) was performed, and C-peptide and glucose were
measured at baseline, and 15, 30, 60 and 120 minutes after the
glucose load. Glucose, fasting insulin and HbA1C were measured
using kinetic methods (ByoSystems, Barcelona, Spain), and C-peptide
was measured by radioimmunoassay (C-PEP II-RIA-CT, DIAsource
ImmunoAssays S.A., Louvain-la-Neuve, Belgium).
Beta-cell function was assessed by calculating the area under the
curve (AUC) of C-peptide levels during an OGTT, using the trap-
ezoidal method [29]. The post-stimulation C-peptide concentrations
constitute a widely-accepted, accurate marker of beta-cell func-
tion among children and adolescents with T2D [30,31]. In addition,
we analyzed the 15-minute C-peptide concentration during OGTT
as a measure of beta-cell function [31]. Finally, we also calculated
the Homeostasis Model Assessment of Beta-cell function (HOMA-
B) index, which is based on the fasting glucose and insulin levels
[32,33]. This index has been shown to characterize beta-cell func-
tion accurately in adolescents [34].
Insulin resistance was measured using the Homeostasis Model
Assessment of Insulin Resistance (HOMA-IR) index [32,33]. The
HOMA-IR index has been shown to correlate closely with well-
established methods for assessing insulin resistance, including the
hyperinsulinemic-euglycemic clamp and minimal models, in pa-
tients with T2D and lean and obese children and adolescents without
T2D [34–37].
Statistical analysis
Initially, we evaluated the distribution of variables using numeric
and graphic methods, and checked for the presence of outliers. Non-
normally distributed, numeric variables were transformed using
simple power functions (logarithmic, inverse, square-root, square,
cubic, etc.), and their distribution was re-checked after transfor-
mation. Variables that were not normalized after transformation
were analyzed in their original form, using non-parametric tests.
Normally-distributed variables were summarized using the mean
and standard deviation (the geometric mean and geometric stan-
dard deviation were used for log-transformed numeric variables),
and the median and interquartile range was used for non-normally
distributed variables. In the bivariate analysis, we compared the dis-
tribution of age, anthropometric and metabolic parameters across
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the three study groups using Analysis of Variance (ANOVA) or the
Kruskal–Wallis test, as appropriate. The association between the AUC
of C-peptide and the duration of T2D among adolescents with T2D
was evaluated using Spearman’s correlation coeﬃcient and its cor-
responding p-value. The assumptions underlying each test were
validated prior to the implementation of the tests. Adjustment for
multiple comparisons was performed using Hommel’s procedure,
a modiﬁcation of Bonferroni’s adjustment that is considerably more
powerful, and maintains adequate protection against type I errors
[38]. Statistical tests were two-sided, and a signiﬁcance level of 5%
was considered relevant. All statistical analyses were conducted using
Stata 13.1 for Windows (StataCorp LP, College Station, Texas, United
States).
Ethical aspects
Patients and their parents or legal guardians signed a written
informed consent prior the onset of the study. This study was ap-
proved by the Institutional Review Board of Universidad Peruana
Cayetano Heredia, in Lima, Peru.
Results
A total of 54 adolescents aged 10–19 years participated in the
study, equally distributed in the three study groups (n = 18). Slightly
over half of the adolescents were male (55.5%), and had a mean age
(±standard deviation) of 16.2 ± 2.5 years. As expected by the study’s
matched design, the sex distribution was identical across the three
study groups, and there were minimal variations in the age distri-
bution across the groups (owing to caliper matching). Themean BMI
of overweight adolescents was higher than that of the lean ado-
lescents (p = 0.002), but was not signiﬁcantly higher than that of
adolescents with T2D (p = 0.081). Adolescents with T2D had a mean
age at diagnosis (±standard deviation) of 14.8 ± 3.0 years, and a
median disease length (interquartile range) of 9.7 (25.3) months.
Half of the adolescents with T2D (n = 9) was obese (BMI for age and
sex at or above the 95th percentile), while 27.7% (n = 5) was over-
weight, but not obese (BMI for age and sex between 85th and 94th
percentile). A family history of T2D was reported in 72.2% of ado-
lescents with T2D (n = 13). The characteristics of the three study
groups are detailed in Table 1.
Mean fasting glucose levels were higher in adolescents with T2D
than in overweight adolescents (p = 0.005) or lean adolescents
(p = 0.001). Mean fasting insulin levels were higher in adolescents
with T2D than in lean adolescents (p = 0.026), but were similar to
those in overweight adolescents (p = 0.993). The HbA1C mean was
higher in adolescents with T2D than in overweight adolescents
(p = 0.001) or lean adolescents (p = 0.001) (Table 2).
The median C-peptide concentrations at 15 minutes during the
OGTT were not statistically different between overweight adoles-
cents (6.8 ng/ml), lean adolescents (3.2 ng/ml) and adolescents with
T2D (4.5 ng/ml) (p = 0.388). However, the median (1st quartile–
3rd quartile) of the HOMA-B index was higher in overweight
adolescents than in lean adolescents [256.9 (162.1–389.8) vs. 134.2
(98.5–238.0); p = 0.015], and adolescents with T2D [256.9 (162.1–
389.8) vs. 119.8 (57.8–347.6); p = 0.011]. No difference in the HOMA-B
index was found between lean adolescents and adolescents with
T2D (134.2 vs. 119.8, p = 0.439) (Table 2).
The median (1st quartile–3rd quartile) of the HOMA-IR scores
was higher in adolescents with T2D than in lean adolescents [6.1
(3.3–8.1) vs. 2.1 (1.4–2.8); p = 0.001], but were similar to those in
overweight adolescents [6.1 (3.3–8.1) vs. 4.0 (2.7–6.0); p = 0.174]
(Table 2 and Fig. 1).
The AUC of glucose during OGTT was higher in adolescents with
T2D compared to overweight adolescents and lean adolescents
Table 1
Characteristics of the study population
Characteristic T2D (n = 18) OW (n = 18) LN (n = 18)
Age (years)a 16.2 ± 2.5 16.1 ± 2.8 16.4 ± 2.4
Sex
Male 10 (55.5) 10 (55.5) 10 (55.5)
Female 8 (44.5) 8 (44.5) 8 (44.5)
Weight (kg)a 74.9 ± 22.1 86.7 ± 24.0 62.9 ± 12.9
Height (m)a 1.6 ± 0.9 1.6 ± 0.1 1.7 ± 0.1
BMI (kg/m2)a 28.8 ± 6.5 32.3 ± 5.3 22.5 ± 2.1
Age at diagnosis (years)a 14.9 ± 3.1 N/A N/A
Disease duration (months)b 9.7 (6.5–31.8) N/A N/A
T2D, adolescents with type 2 diabetes; OW, overweight/obese adolescents; LN, lean
adolescents; BMI, body mass index; N/A, not applicable.
a Mean ± standard deviation.
b Median (1st quartile–3rd quartile); Otherwise, n (%).
Table 2
Fasting serum glucose, insulin, glycated hemoglobin (HbA1C), 15-minute C-peptide (15-min C-peptide), and Homeostasis Model Assessment for Insulin Resistance Index
(HOMA-IR) and β-cell function (HOMA-B)
Characteristic T2D (n = 18) OW (n = 18) LN (n = 18) Global p-value
Fasting glucose (mmol/l)a 7.3 ± 2.8 5.90 ± 0.4 4.6 ± 0.5 <0.001
Fasting insulin (pmol/l)b 119.2 ± 2.3 121.4 ± 1.8 58.2 ± 2.3 0.007
HbA1C (%)a 8.4 ± 2.9 5.4 ± 0.4 5.4 ± 0.4 <0.001
15-min C-peptide (ng/ml)c 4.5 (1.3–6.4) 6.8 (3.3–11.0) 3.2 (0.9–7.8) 0.388
HOMA-B indexc 119.8 (57.8–347.6) 256.9 (162.1–389.8) 134.2 (98.5–238.0) 0.015
HOMA-IR indexc 6.1 (3-3-8.1) 4.0 (2.7–6.0) 2.1 (1.4–2.8) <0.001
T2D, adolescents with type 2 diabetes; OW, overweight/obese adolescents; LN, lean adolescents; BMI, body mass index; N/A, not applicable.
a Arithmetic mean ± standard deviation.
b Geometric mean ± geometric standard deviation.
c Median (1st quartile-3rd quartile).
Figure 1. Homeostatic model assessment for insulin resistance (HOMA-IR) in pa-
tients with T2D, overweight, and lean (●) adolescents.
17H. Zelada et al. / Journal of Clinical & Translational Endocrinology 5 (2016) 15–20
(p < 0.001), but there was no difference between the glucose AUC
of lean and overweight adolescents (p = 0.318) (Fig. 2). Regarding
the AUC of C-peptide, there was no signiﬁcant difference between
the three study groups (p = 0.215) (Fig. 3). There was no correla-
tion between disease length and AUC of C-peptide (Spearman’s
correlation coeﬃcient = −0.21; p = 0.415).
Discussion
Main ﬁndings
The present study shows that insulin resistance is themost prom-
inent characteristic, rather than beta-cell dysfunction, among
Peruvian adolescents with T2D. The median HOMA-IR score was
higher in adolescents with T2D compared to lean adolescents
(6.1 vs. 2.1; p = 0.002), but it was not different from overweight ado-
lescents (6.1 vs. 4.0; p = 0.322); and although the median AUC of
C-peptide in adolescents with T2D was lower than overweight and
lean adolescents, this differencewas not statistically signiﬁcant (230.7
vs. 336.6 vs. 267.3 nmol/l/120 min, respectively; p = 0.215).
It is not feasible to assess beta-cell mass, but it is possible to assess
beta-cell function by glucose tolerance test. In our study, the most
outstanding ﬁndings were that the AUC of glucose during OGTT was
signiﬁcantly higher in adolescents with T2D than in lean adoles-
cents without T2D, while the AUC of C-peptide were not signiﬁcant
among the three study groups, that beta cell dysfunction was not
signiﬁcant different in these three groups.
Themean of HbA1c of the participants in the studywas 8.4% ± 2.9,
which is lower compared to a study of the International Diabetes
Federation (8.9 ± 0.6) [27], while it was higher a recent one done
in Caucasians and African Americans (6.6 ± 1.0) [9]. The possible
factors that might explain these differences in Hba1c, as a meta-
bolic control marker, may be related to the genetic predisposition
for insulin resistance in the pathogenesis of T2D in different pop-
ulation groups.
Role of race on insulin resistant and beta-cell dysfunction
Race and genetics are important factors to consider as poten-
tial determinants of the pathophysiology of T2D in youth. The genetic
contribution to the pathophysiology of T2D are based on several
identiﬁed genetic polymorphisms linked to T2D in youth, such as
CC polymorphism of Apolipoprotein A-II (APOA-II) [39]. Also, a recent
publication has identiﬁed SLC16A11, as a novel candidate gene for
developing T2D, in Mexican people which is also possible may have
a role in triacylglycerol metabolism; ﬁndings that conﬁrm the im-
portant role of genetics in the development of T2D predisposition
[40].
Different studies have aimed to identify the main processes in
the T2D pathophysiology in youth, but most of these studies have
Figure 2. (A) Plasmatic glucose and (B) C-peptide concentrations during the oral glucose tolerance test in patients with T2D (○), overweight (▲), and lean (■) adolescents.
Figure 3. (A) Box-and-whisker plots of the area under the curve (AUC)* of plasmatic glucose and (B) C-peptide during the oral glucose tolerance test in patient with T2D,
overweight, and lean adolescents.
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included children and adolescents in North-Americas. They showed
that a rapid deterioration of beta cell function over time is the
principal characteristic in T2D in youth, with no signiﬁcant change
in insulin sensitivity [9,41,42]. Expanding on these ﬁndings, the
TODAY trial [43] showed that metformin and lifestyle modiﬁca-
tion are insuﬃcient to maintain an adequate glucose balance in
adolescents with T2D, probably because insulin resistance is not the
predominant characteristic at the onset of diabetes.
Opposite to our ﬁndings, a multi-ethnic study [44] showed that
obese adolescents with normal glucose tolerance who progressed
to Impaired Glucose tolerance (IGT) had a normal beta-cell func-
tion at the beginning of the study, proposing insulin deﬁciency as
the main mechanism of action. Despite of its prospective nature,
the study is limited in that it evaluates a heterogeneous, multi-
ethnic group, and did not analyze the progression to IGT in Hispanics.
Regarding studies of T2D in Hispanic youth, a community-
based study in Mexico found a high prevalence of pre-diabetes in
children, and a higher prevalence of T2D among the obese [45].
However, the majority of the studies about T2D in Hispanic chil-
dren and adolescents have only included children and adolescents
of Hispanic descent who were raised (and even born) in devel-
oped countries. As stated above, this is important because the Latino
adolescents born and raised in a South American settingmay possess
unique genetic and environmentally- determined characteristics that
could inﬂuence the pathogenesis of T2D. Nevertheless, previous
studies have reported that Hispanic children have greater insulin
resistance than Caucasian, and, that the second phase insulin se-
cretion is greater in Hispanic than in African-American youth [18].
In addition, a high prevalence of obesity and metabolic syndrome
reﬂected by a high HOMA-IR was found in Latin American youth
living in Spain (compared to Caucasian Spanish youth) [46]. Also,
it has been found a negative correlation between adiponectin and
insulin resistance among Mexican youth, ﬁndings that could be
linked to their genetic background [47]. A possible reason of these
ﬁndings can be related to the fact that Hispanics are genetically
linked to the Pima Indians of Arizona, in whom the natural history
of T2D starts with insulin resistance, which is later followed by an
impairment in insulin secretion [48,49].
This study expands the existing literature by focusing in ado-
lescents born and raised in a South American country. Evidence on
the pathophysiology of T2D is limited in this group, despite the po-
tential inﬂuence exerted by genetic and environmental factors unique
to this population. We believe it is important to understand the
pathophysiology of T2D in youth because several metabolic changes
occurring in puberty render its treatment challenging, including the
reduction in insulin sensitivity secondary to an increase secretion
of growth hormone [50], testosterone, estrogens and an increase
of fat mass [51]. This challenge is even greater in LMICs, such as Peru,
as adolescents with T2D may exhibit a poor metabolic control and
are overweight at the time of the diagnosis [52].
Limitations and strengths
The cross-sectional nature of the study may constitute a limi-
tation, as many cases will have established disease, and some
associations may be confounded by disease duration; however, the
study results are important (albeit preliminary) because this is a
novel study done with patients born and raised in a Latin Ameri-
can country. Second, selection bias could have resulted from the
selection of participants in a private research center, instead of
primary care facilities or the population. The strength of this study
was based on the standardized assessment conducted by one health-
care staff in order achieves an accurate diagnosis of the three groups
studied, as well as the use of one of the main diabetes research
centers in Lima to perform the study. Another strength is that we
have considered lean adolescents as an additional group, who were
matched with adolescents with T2D and overweight adolescents.
This addition allows a better assessment of the role of both over-
weight and diabetes on glucose metabolism. In addition to that, we
determined that all T2D adolescents did not have T1D, did not have
clinical suspicion of maturity onset diabetes of the young (MODY)
as well as other hybrid diabetes states.
Conclusion
Insulin resistance is the main characteristic in adolescents di-
agnosed with T2D born and raised in a Latino country, such as Peru.
Improving insulin resistance, through diet and pharmacologic treat-
ment in this target group, may contribute to have an adequate control
of T2D.
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